![conference banner](/images/conference-banner.jpeg)
Abstract
Aims: Treatment with statins has significantly reduced cardiovascular morbidity and mortality, an effect attributed to both the low-density lipoprotein cholesterol (LDL-C) lowering capacity and the pleiotropic actions of these drugs. However, residual risk remains even after intense LDL-C lowering. Therefore, additional treatment with lipid-lowering drugs which improve other lipid parameters and have favourable non-lipid effects may be of clinical value. The aim of the present article is to review the actions of nicotinic acid and comment on the limitations and possible benefits of this drug in clinical practice. Methods: Relevant articles were identified through a Pubmed search up to July 2010. Results: Nicotinic acid (niacin) improves the lipid profile and has been associated with reduction in morbidity and mortality from cardiovascular disease. This favourable outcome may be due to several beneficial actions of this drug, such as antithrombotic, anti-inflammatory and antioxidant. However, its use has been limited due to side effects, especially flushing. A novel formulation with a prostaglandin D2 receptor antagonist (laropiprant) appears to substantially decrease the frequency and intensity of flushing, without affecting the other properties of niacin. Some concerns regarding treatment with nicotinic acid include impaired glucose metabolism and elevations in uric acid and homocysteine levels. Conclusion: Nicotinic acid is a safe supplementary (to statins) lipid lowering agent which may also improve cardiovascular outcomes. Whether its combination with laropiprant will be proved equally effective and more favourable in terms of adverse effects remains to be established by large clinical trials.
Keywords: Nicotinic acid, niacin, laropiprant, antithrombotic, anti-inflammatory, antioxidant, high-density lipoprotein, cardiovascular, coronary heart disease, very low-density lipoprotein
Current Vascular Pharmacology
Title: Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation
Volume: 9 Issue: 4
Author(s): Matilda Florentin, Evangelos N. Liberopoulos, Anastazia Kei, Dimitri P. Mikhailidis and Moses S. Elisaf
Affiliation:
Keywords: Nicotinic acid, niacin, laropiprant, antithrombotic, anti-inflammatory, antioxidant, high-density lipoprotein, cardiovascular, coronary heart disease, very low-density lipoprotein
Abstract: Aims: Treatment with statins has significantly reduced cardiovascular morbidity and mortality, an effect attributed to both the low-density lipoprotein cholesterol (LDL-C) lowering capacity and the pleiotropic actions of these drugs. However, residual risk remains even after intense LDL-C lowering. Therefore, additional treatment with lipid-lowering drugs which improve other lipid parameters and have favourable non-lipid effects may be of clinical value. The aim of the present article is to review the actions of nicotinic acid and comment on the limitations and possible benefits of this drug in clinical practice. Methods: Relevant articles were identified through a Pubmed search up to July 2010. Results: Nicotinic acid (niacin) improves the lipid profile and has been associated with reduction in morbidity and mortality from cardiovascular disease. This favourable outcome may be due to several beneficial actions of this drug, such as antithrombotic, anti-inflammatory and antioxidant. However, its use has been limited due to side effects, especially flushing. A novel formulation with a prostaglandin D2 receptor antagonist (laropiprant) appears to substantially decrease the frequency and intensity of flushing, without affecting the other properties of niacin. Some concerns regarding treatment with nicotinic acid include impaired glucose metabolism and elevations in uric acid and homocysteine levels. Conclusion: Nicotinic acid is a safe supplementary (to statins) lipid lowering agent which may also improve cardiovascular outcomes. Whether its combination with laropiprant will be proved equally effective and more favourable in terms of adverse effects remains to be established by large clinical trials.
Export Options
About this article
Cite this article as:
Florentin Matilda, N. Liberopoulos Evangelos, Kei Anastazia, P. Mikhailidis Dimitri and S. Elisaf Moses, Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation, Current Vascular Pharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157016111796197279
DOI https://dx.doi.org/10.2174/157016111796197279 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
On Some Physiological Aspects of Ethanol Repercussion on Neural and Cardiorenal Functions
Central Nervous System Agents in Medicinal Chemistry Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Emerging P2Y12 Receptor Antagonists: Role in Coronary Artery Disease
Current Vascular Pharmacology Viral Heart Disease and Acute Coronary Syndromes - Often or Rare Coexistence?
Current Pharmaceutical Design Tea Consumption and Risk of Ischemic Stroke: a Brief Review of the Literature
Current Pharmaceutical Biotechnology Effects of Lipid-Lowering Drugs on Adiponectin
Current Vascular Pharmacology Perivascular Inflammation and Hypertensive Cardiovascular Remodeling
Current Hypertension Reviews Salusins in Hypertension and Related Cardiovascular Diseases
Current Drug Metabolism Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin
Current Pharmaceutical Design Tuning Immune Suppression in Systemic Autoimmunity with Self-Derived Peptides
Inflammation & Allergy - Drug Targets (Discontinued) Novel Plant Sterol and Stanol Derivatives with Beneficial Properties:Efficacy and Safety
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Effects of Acarbose on Proinsulin and Insulin Secretion and their Potential Significance for the Intermediary Metabolism and Cardiovascular System
Current Diabetes Reviews Vitamin D Supplementation for Obesity: Potential Mechanisms of Action and an Update of Randomized Controlled Trials
Current Nutrition & Food Science Seasonal Allergic Rhinitis is Effectively Assuaged With an Essential Oil Inhaler (AromaStick®): Results From a Randomized, Controlled, Double-blind Effectiveness Trial
The Natural Products Journal Therapeutic Strategies in the Treatment of Diabetic Nephropathy - a Translational Medicine Approach
Current Medicinal Chemistry Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies
Vascular Disease Prevention (Discontinued) Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets VIP in Inflammatory Bowel Disease: State of the Art
Endocrine, Metabolic & Immune Disorders - Drug Targets Longevity Pathways: HSF1 and FoxO Pathways, a New Therapeutic Target to Prevent Age-Related Diseases
Current Aging Science Incretins and Preservation of Endothelial Function
Cardiovascular & Hematological Agents in Medicinal Chemistry